AUD 0.05
(1.89%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 | 291.06 Thousand AUD | -42.53% |
2023 | 506.44 Thousand AUD | 12.52% |
2022 | 450.1 Thousand AUD | 109.54% |
2021 | 214.8 Thousand AUD | -18.7% |
2020 | 264.21 Thousand AUD | 170.68% |
2019 | 97.61 Thousand AUD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 FY | 291.06 Thousand AUD | -42.53% |
2024 Q2 | 355.97 Thousand AUD | 0.0% |
2024 Q4 | 291.06 Thousand AUD | 0.0% |
2024 Q3 | 291.06 Thousand AUD | -18.23% |
2024 Q1 | 355.97 Thousand AUD | -29.71% |
2023 FY | 506.44 Thousand AUD | 12.52% |
2023 Q4 | 506.44 Thousand AUD | 0.0% |
2023 Q3 | 506.44 Thousand AUD | 1.76% |
2023 Q2 | 497.7 Thousand AUD | 0.0% |
2023 Q1 | 497.7 Thousand AUD | 10.58% |
2022 Q2 | 322.14 Thousand AUD | 0.0% |
2022 FY | 450.1 Thousand AUD | 109.54% |
2022 Q4 | 450.1 Thousand AUD | 0.0% |
2022 Q3 | 450.1 Thousand AUD | 39.72% |
2022 Q1 | 322.14 Thousand AUD | 49.97% |
2021 Q4 | 214.8 Thousand AUD | 0.0% |
2021 Q3 | 214.8 Thousand AUD | 0.0% |
2021 Q1 | - AUD | 0.0% |
2021 FY | 214.8 Thousand AUD | -18.7% |
2020 FY | 264.21 Thousand AUD | 170.68% |
2019 FY | 97.61 Thousand AUD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Mayne Pharma Group Limited | 688.98 Million AUD | 99.958% |